Vivos Therapeutics (VVOS) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- US stocks set for higher open as AI trade steadies; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 6% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mailGet Alerts VVOS Hot Sheet
Join SI Premium – FREE
Vivos Therapeutics (NASDAQ: VVOS) reported Q1 EPS of ($0.52), $0.07 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $7.5 million.
For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Anthropic PBC: adjusted operating income increased for the three months ended September 30, 2026 to $2.5 billion
- MasTec (MTZ) PT Lowered to $270 at Cantor Fitzgerald
- Caterpillar (CAT) PT Lowered to $685 at DA Davidson
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
